Werewolf Therapeutics Inc. reported its third quarter 2025 financial results and issued a business update highlighting progress across its clinical pipeline. The company announced that it will provide an update on the interim data from the Phase 1/1b clinical trial of WTX-124, as well as insights from the End of Phase 1 meeting with the FDA, later in the fourth quarter of 2025. WTX-124, which recently received Fast Track Designation, is being evaluated for its path to a registration-enabling trial in advanced or metastatic cutaneous melanoma. Werewolf also plans to share an update on the Phase 1b/2 trial of WTX-330, including a potential further development plan, in the same timeframe. The company continues IND-enabling studies for WTX-1011, its first INDUCER™ T-cell engager targeting STEAP1, and expects to nominate a differentiated target candidate by year-end. Additionally, Werewolf will present pharmacokinetic data on WTX-124 at the 2025 SITC Annual Meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567757-en) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.